TS
Elite in Non-Small Cell Lung Cancer (NCSLC)
Check Dr. Thomas E. Stinchcombe's experience treating your condition:
About Dr. Thomas E. Stinchcombe

Thomas Stinchcombe is an Oncologist and a Hematologist Oncology expert in Durham, North Carolina. Stinchcombe has been practicing medicine for over 27 years and is rated as an Elite expert by MediFind in the treatment of Non-Small Cell Lung Cancer (NCSLC). He is also highly rated in 14 other conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NCSLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery. He is licensed to treat patients in North Carolina. Stinchcombe is currently accepting new patients.

His clinical research consists of co-authoring 142 peer reviewed articles and participating in 22 clinical trials in the past 15 years. In particular, he has co-authored 113 articles and participated in 18 clinical trials in the study of Non-Small Cell Lung Cancer (NCSLC).

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Thomas E. Stinchcombe it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
Locations
20 Duke Medicine Cir, Durham, NC 27710
Background & Education
Graduate Institution
University Of Virginia School Of Medicine, 1995
Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke Regional Hospital
UNC Medical Center
Duke University Hospital
Duke Raleigh Hospital
Languages Spoken
English
Arabic
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


20 Clinical Trials

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Phase 2 Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors in Refractory ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
A Single Arm Phase II Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
A Phase II Study of Treatment of Brain Metastases From Non-Small Cell Lung Cancer With Concurrent Whole Brain Radiation Therapy and Pemetrexed
Single Arm Phase 2 Trial of Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib (TOP 1901)
A Phase I Trial of Carboplatin and Abraxane in Patients With Solid Tumors
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History
Phase II Clinical Trial of Carboplatin and Abraxane in Patients With Extensive Stage Small Cell Lung Cancer
A Randomized Phase II Trial of Erlotinib Alone or in Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
Phase I Trial of Abraxane in Combination With Gemcitabine in Patients With Solid Tumors
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Phase II Study of Vinflunine and Cetuximab in the Second Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer
Randomized Phase II Study of First-Line Treatment With Gemcitabine vs. Erlotinib vs. Gemcitabine and Erlotinib in Elderly Patients With Stage IIIB/IV Non-Small Cell Lung Cancer
A Phase II Trial of Carboplatin, Ixabepilone and Cetuximab in Chemotherapy Naive Advanced Non-Small Cell Lung Cancer
A Two Arm Phase I Trial of Sorafenib in Combination With Cisplatin/Etoposide or Carboplatin/Pemetrexed in Patients With Solid Tumors
Phase I/II Trial of Induction Carboplatin/Paclitaxel With Bevacizumab Followed by Concurrent Thoracic Conformal Radiation Therapy With Carboplatin/Paclitaxel, Bevacizumab and Erlotinib in Stage IIIA/B Non-Small Cell Lung Cancer
A Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C Mutation
View 17 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Elite
Elite
Elite